New targeted drug shows promise for chinese patients with Hard-to-Treat cancers
NCT ID NCT04380753
First seen Mar 26, 2026 · Last updated May 22, 2026 · Updated 6 times
Summary
This early-phase study tested a drug called sotorasib (AMG 510) in 12 people of Chinese descent with advanced solid tumors that have a specific KRAS G12C mutation. The main goals were to check safety and how the drug moves through the body. While the drug aims to shrink tumors, this trial focused on finding the right dose and watching for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS WITH KRAS P.G12C MUTATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Taiwan University Hospital
Taipei, 10002, Taiwan
-
Prince of Wales Hospital
Shatin, New Territories, Hong Kong
-
University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong
-
Veterans General Hospital - Taichung
Taichung, 40705, Taiwan
Conditions
Explore the condition pages connected to this study.